Angiogenic factors during pregnancy: Indicators of preeclampsia;Angiogenesefaktoren in der schwangerschaft: Indikatoren für die präeklampsie

Geburtshilfe und Frauenheilkunde

Volumn 67, Issue 3, 2007, Pages 228-235

  Schmidt, Markus ^a   Gellhaus, A ^a   Kasimir Bauer, S ^a   Winterhager, E ^a   Kimmig, R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Angiogenic factors; CYR61; Hypertension; NOV; Placentation; Preeclampsia

Indexed keywords

ANGIOGENIC FACTOR; CYSTEINE RICH PROTEIN 61; PLACENTAL GROWTH FACTOR; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; DISEASE PREDISPOSITION; ENZYME ACTIVITY; HUMAN; PLACENTA DEVELOPMENT; PREECLAMPSIA; PREGNANCY; PROTEIN EXPRESSION; REVIEW; TROPHOBLAST;

EID: 34248651819     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-964944     Document Type: Review

References (86)

1. Schulz M, Wacker J. Epidemiologie der Präeklampsie. In: Heilmann L, Rath W (Hrsg). Schwangerschaftshochdruck. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2002: 215-222
2. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report. Am J Obstet Gynecol 2002; 183: 1-22
3. Brown MA, Lindheimer MD, de Swiet M et al. The classification and diagnosis of hypertensive disotder of pregnancy. Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertension in Pregnancy 2001; 20: 20-30
4. Rath W. Hypertensive Schwangerschaftserkrankungen. In: Rath W, Friese K (Hrsg). Erkrankungen in der Schwangerschaft. Stuttgart, New York: Thieme, 2005: 73-97
5. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102: 181-192
6. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG 2004; 111: 298-302
7. Hauth JC, Ewell MG, Levine RI, Esterlitz JR, Sibai BM, Curet LB. Pregnancy outcome in healthy nulliparous women who subsequently developed hypertension. Obstet Gynecol 2000; 95: 24-28
8. Sibai BM, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799
9. Huppertz B, Peters LLH. Vascular biology in implantation and placentation. Angiogenesis 2005; 8: 157-167
10. Craven CM, Morgan T, Ward K. Decidual spiral artery remodelling begins before cellular interaction with cytotrophoblasts. Placenta 1998; 19: 241-252
11. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: Implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003; 69: 1-7
12. Benirschke K, Kaufmann P. Pathology of the Human Placenta, 4th ed. New York: Springer, 2000
13. Hirano H, Imai Y, Ito H. Spiral artery of placenta: Development and pathology - immunohistochemical, microscopical, and electron-microscopic study. Kobe J Med Sci 2002; 48: 13-23
14. Jauniaux E, Hempstock J, Greenwold N, Burton GJ. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies. Am J Pathol 2003; 162: 115-125
15. Hustin J, Jauniaux E, Schaaps JP. Histological study of the materno-embryonic interface in spontaneous abortion. Placenta 1990; 11: 477-486
16. Brosens IA. The utero-placental vessels at term - the distribution and extent of physiological changes. Trophoblast Res 1988; 3: 61-67
17. Sheppard BL, Bonnar J. The maternal blood supply to the placenta in pregnancy complicated by intrauterine fetal growth retardation. Trophoblast Res 1988; 3: 69-81
18. Kadyrov M, Schmitz C, Black S, Kaufmann P. Huppertz B. Pre-eclampsia and maternal anaemia display reduced apoptosis and opposite invasive phenotypes of extravillous trophoblast. Placenta 2003; 24: 540-548
19. Lam Ch, Lim K-H, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46: 1077-1085
20. Te Velde EA, Exalto N, Hesseling P, van der Linden HC. First trimester development of human chorionic villous vascularization studied with CD34 immunohistochemistry. Hum Reprod 1997; 12: 1577-1581
21. Jauniaux E, Burton GJ, Moscoso GJ, Hustin J. Development of the early human placenta: a morphometric study. Placenta 1991; 12: 269-276
22. Jackson MR, Mayhew TM, Boyd PA. Quantitative description of the elaboration and maturation of villi from 10 weeks of gestation to term. Placenta 1992; 13: 357-370
23. Mayhew TM. Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. Placenta 2002; 23: 742-750
24. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization Systematic Review of Screenings Tests for Preeclampsia. Obstet Gynecol 2004; 104: 1367-1391
25. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201
26. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676
27. Gerber HP, Mc Murtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343
28. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985
29. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039
30. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C Declerq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439
31. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442
32. Persico M, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PLGF). Curr Topics Microbiol Immunol 1999; 237: 31-40
33. Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI, Rollason T. Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors 1995; 12: 235-243
34. Clark D, Smith S, Licence D, Evans A, Charnock-Jones D. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 1998; 159: 459-467
35. Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 2006; 27: 70-78
36. Terman BI, Dougher-Vermazen M, Carrion ME. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Comm 1992; 187: 1579-1586
37. Shibuya M, Yamagucgi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-524
38. Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 2003; 286: H153-H164
39. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18
40. Hunter A, Aitkenhead M, Caldwell C, McCracken G, Wilson D, McClure N. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension 2000; 36: 965-969
41. Tsatsaris V, Goffin F, Munaut C, BrichantJF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-5563
42. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFLT-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191: 1240-1246
43. Helske S, Vuorela O, Carpen C, Horning C, Weich H, Halmesmake E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001; 7: 205-210
44. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348-2351
45. Schlembach D, Fischer T, Meurer B, Strick R, Strissel P, Beckmann MW. Angiogenetische Faktoren bei Praeklampsie und intrauteriner Wachstumsretardierung. Geburtsh Frauenheilk 2003; 63: 12
46. Stepan H, Geide A, Faber R. sFlt1 als prognostischer Marker für Präeklampsie und IUGR. Geburtsh Frauenheilk 2005; 66: S1
47. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-775
48. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177-182
49. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405-1423
50. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111: 649-658
51. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549-560
52. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schistermann EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683
53. Torry DS, Mukherjea D, Arroyo J, Torry RJ. Expression and function of placental growth factor: implications for abnormal placentation. J Soc Gynecol Invest 2003; 10: 178-188
54. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267-1272
55. Bersinger NA, Odegard RA. Second and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83: 3745
56. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187: 127-136
57. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PLGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23:101-111
58. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266-1274
59. Su YN, Lee CN, Cheng WF, Shau WY, Chow SN, Hsieh FJ. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001; 97: 898-904
60. Wolf M, Shah A, Lam C, Martinez A, Smirnakis KV, Epstein FH, Taylor RN, Ecker JL, Karumanchi SA, Thadhani R. Circulating levels of the angiogenic markers sFLT-1 are increased in first versus second pregnancies. Am J Gyn Obstet 2005; 193: 16-22
61. Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA 1991; 266: 237-241
62. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillmann IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFLT1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
63. Perbal B. NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 2001; 54: 57-79
64. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62-64
65. Rachal AW, Brigstock DR. Structural and functional properties of CCN proteins. Vitamines and Hormones 2005; 70: 69-103
66. Bleau AM, Planque N, Perbal B. CCN proteins and cancer: two to tango. Front Biosci 2005; 10: 998-1009
67. Kolesnikova TV, Lau LF. Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells. Oncogene 1998; 16: 747-754
68. Li CL, Martinez V, Hem B, Lombet A, Perbal B. A role for CCN3 (NOV) in calcium signaling. Mol Pathol 2002; 55: 250-261
69. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998; 95: 6355-6360
70. Ellis PD, Chen Q, Barker PJ, Metcalfe JC, Kemp PR. NOV gene encodes adhesion factor for vascular smooth muscle cells and is dynamically regulated in response to vascular injury. Arterioscler Thromb Vasc Biol 2000; 20: 1912-1919
71. Ellis PD, Metcalfe JC, Hyvonen M, Kemp PR. Adhesion of endothelial cells to NOV is mediated by the integrins alphavbeta3 and alpha5beta1. J Vasc Res 2003; 40: 234-243
72. Leu SJ, Lam SC, Lau LF. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem 2002; 277: 46248-46255
73. Lin CG, Leu SJ, Chen N, Tebeau CM, Lin SX, Yeung CY, Lau LF. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem 2003; 278: 24200-24208
74. Chen N, Leu SJ, Todorovic V, Lam SC, Lau LF. Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J Biol Chem 2004; 279: 44166-44176
75. Mo FE, Muntean AG, Chen CC, Stolz DB, Watkin SC, Lau LF. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002; 22: 8709-8720
76. Gellhaus A, Schmidt M, Dunk C, Lye STJ, Kimmig R, Winterhager E. Decreased expression of angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia. Mol Hum Reprod 2006; 12: 389-399
77. Castellucci M, Scheper M, Scheffen I, Celona A, Kaufmann P. The development of the human placental villous tree. Anat Embryol 1990; 181: 117-128
78. Benirschke K, Kaufmann P (eds). Pathology of the Human Placenta. 4th ed. New York: Springer-Verlag, 2000
79. Kaufmann P, Mayhew TM, Charnock-Jones DS. Aspects of human feto-placental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta 2004; 25: 114-126
80. Mayhew TM, Wijesekara J, Baker PN, Ong SS. Morphometric evidence that villous development and fetoplacental angiogenesis are compromised by intrauterine growth restriction but not by preeclampsia. Placenta 2004; 25: 829-833
81. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Pre-eclampsia and fetal growth restriction: How morphometrically different is the placenta? Placenta 2006; 27: 727-734
82. Bohn H, Kraus W, Winckler W. Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17). Oncodev Biol Med 1983; 4: 343-350
83. Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, Janaky T, Boronkai A, Kliman H, Meiri H, Bohn H, Than GN, Sumegi B. Functional analyses of placental protein 13/galectin-13. Eur J Biochem 2004; 271: 1065-1078
84. Visegrady B, Than NG, Kilar F, Sümegi B, Than GN, Bohn H. Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). Prot Eng 2001; 14: 875-880
85. Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, Mandel S, Rabinovitch, Paltieli Y, Admon A, Gonen R. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004; 25: 608-622
86. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, Tal J, Cuckles HS. A novel approach to first-trimester screening for early preeclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006; 27: 13-17